Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors

PURPOSE: The CYP17A1 inhibitor abiraterone markedly reduces androgen precursors and is thereby effective in castration-resistant prostate cancer (CRPC). However, abiraterone increases progesterone, which can activate certain mutant androgen receptors (ARs) identified previously in flutamide-resistan...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Chen, Eddy J., Sowalsky, Adam G., Gao, Shuai, Cai, Changmeng, Voznesensky, Olga, Schaefer, Rachel, Loda, Massimo, True, Lawrence D., Ye, Huihui, Troncoso, Patricia, Lis, Rosina L., Kantoff, Philip W., Montgomery, Robert B., Nelson, Peter S., Bubley, Glenn J., Balk, Steven P., Taplin, Mary-Ellen
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4359958/
https://ncbi.nlm.nih.gov/pubmed/25320358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1220
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados